The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)].
 
Juan Maurel
No Relationships to Disclose
 
Carlos Fernandez-Martos
No Relationships to Disclose
 
Marta Martin-Richard
No Relationships to Disclose
 
Vicente Alonso
No Relationships to Disclose
 
Jose Carlos Mendez
No Relationships to Disclose
 
Antonia Salud
No Relationships to Disclose
 
Carles Pericay
No Relationships to Disclose
 
Jorge Aparicio
No Relationships to Disclose
 
Javier Gallego
No Relationships to Disclose
 
Alberto Carmona
No Relationships to Disclose
 
Enrique Casado
No Relationships to Disclose
 
Hermini Manzano
No Relationships to Disclose
 
Carlos Horndler
No Relationships to Disclose
 
Michele Rubini
No Relationships to Disclose
 
Miriam Cuatrecasas
No Relationships to Disclose
 
Xabier Garcia-Albeniz
No Relationships to Disclose
 
Jaime Feliu
No Relationships to Disclose